Trials / Completed
CompletedNCT00092586
Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)
A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholesterolemia Who Have Not Reached National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Target LDL-Cholesterol Level
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,904 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this 6-week study is to compare the reduction in specific levels of cholesterol in patients with high cholesterol.
Detailed description
The duration of treatment is 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0653, ezetimibe | |
| DRUG | Comparator: statins |
Timeline
- Start date
- 2002-09-01
- Primary completion
- 2003-10-01
- Completion
- 2003-10-01
- First posted
- 2004-09-28
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00092586. Inclusion in this directory is not an endorsement.